Medical Condition News

RSS

King submits ACUROX NDA to FDA

King Pharmaceuticals®, Inc. and Acura Pharmaceuticals, Inc. today announced that King has submitted a New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets to the U.S. Food and Drug Administration (FDA), including a request for priority review classification. ACUROX® is an immediate release tablet containing oxycodone HCl intended for the relief of moderate to severe pain.

20 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders, which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers.

20 Dec 2010

Hyperpriming in early stages of Alzheimer's disease explained

The capacity to remember that a zebra has stripes, or that a giraffe is a four-legged mammal, is known as semantic memory. It allows us to assign meaning to words and to recall general knowledge and concepts that we have learned. The deterioration of these capacities is a defining feature of semantic dementia and can also occur in Alzheimer's disease.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Dell receives CEO Cancer Gold Standard accreditation

Dell has received CEO Cancer Gold Standard™ accreditation, recognizing the company's commitment to reducing the cancer risk of its employees and their families by encouraging healthy lifestyles and promoting early detection through screenings, and by providing quality care, including access to cancer clinical trials, when a cancer diagnosis becomes a reality.

20 Dec 2010

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

20 Dec 2010

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

Progress report on 'Strategy for Europe on nutrition, overweight and obesity'

December has been a busy month for the European Commission, and Despina Spanou, Principal Adviser at the Directorate General for Health and Consumers, talks to EUFIC, about Europe's Nutrition Strategy mid-term progress report, the evaluation of the EU Platform for Action on Diet, Physical Activity and Health, the OECD/EC report "Health at a Glance: Europe 2010", and the Belgian Presidency/EC Conference on Monitoring and Evaluation of EU and Member States' strategies on nutrition, overweight and obesity-related health issues.

20 Dec 2010

NAFC forms council to establish independent quality standards for incontinence products

The National Association For Continence (NAFC) is heading a newly formed council with the objective of establishing national, independent quality standards for disposable adult absorbent products provided by states to Medicaid waiver recipients cared for in their private homes rather than as residents of a state-funded nursing home.

20 Dec 2010

Comprehensive guidance for care providers on Dementia Care Mapping process

Dementia is a critical health concern, but are the current care services able to offer appropriate support? Only a few days ago, the review by the Royal College of Psychiatrists found many dementia patients were not getting the support on nutrition and mental health that they should. The need for improved care is higher than ever.

20 Dec 2010

Phadia to market diagnostic products in India

Import, sales and distribution of Phadia's allergy, asthma and autoimmunity diagnostics products, including ImmunoCAP and EliA, have been commercially approved by the Indian authorities.

20 Dec 2010

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

SEEK, a leading UK privately-owned drug-discovery group, is pleased to announce the establishment of a new joint venture entity with Pernix Therapeutics Holdings, an integrated specialty pharmaceutical company focused primarily on the United States pediatric market.

20 Dec 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. In the United States alone, there are more than 250,000 people living with SCI; approximately three million worldwide are affected.

20 Dec 2010

Novartis' Gilenya uptake to increase

A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.

20 Dec 2010

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called "monensin" prevents the growth of prostate cancer cells. Monensin is used in the meat and dairy industry, for example.

20 Dec 2010

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces positive pre-clinical results from its in-house product candidate C3BS-GQR-1, to treat patients suffering from acute myocardial infarction in order to protect cardiac tissue from damage and direct heart stem cells to mature and restore pump function.

20 Dec 2010

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.

20 Dec 2010

Medical Condition News

King submits ACUROX NDA to FDA

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Hyperpriming in early stages of Alzheimer's disease explained

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Exciting progress made in MS research during 2010

Dell receives CEO Cancer Gold Standard accreditation

VIVUS seeks marketing approval of QNEXA in the EU

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Progress report on 'Strategy for Europe on nutrition, overweight and obesity'

NAFC forms council to establish independent quality standards for incontinence products

Comprehensive guidance for care providers on Dementia Care Mapping process

Phadia to market diagnostic products in India

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Novartis' Gilenya uptake to increase

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News